Genentech Introduces $50 Cash Option for Flu Treatment Xofluza

Genentech has launched a Direct-to-Patient program for its antiviral drug Xofluza, offering a $50 cash option to enhance access for those underinsured or uninsured.

Genentech announced its first Direct-to-Patient program on Thursday, providing a $50 cash payment option for its influenza medication Xofluza, reducing the list price by 70%.
The initiative primarily targets patients who are underinsured, uninsured, or self-pay, improving access to the antiviral drug Baloxavir marboxil amid rising healthcare costs.
As a member of the Roche Group, Genentech aims to bridge gaps in insurance coverage for flu treatments, addressing the needs of those most affected by influenza.

Why It Matters

This program reflects a growing trend in the pharmaceutical industry towards improving access to medications, particularly for vulnerable populations. By making Xofluza more affordable, Genentech is addressing critical public health needs in managing influenza outbreaks.